The study of the fourth vaccine revealed: "Good for Delta - but not for Leumicron""

January 17, 2022   

Prof. Gili Regev Yohai, who led the trial conducted at Sheba Hospital on the effect of the fourth dose in protecting against the coronavirus, presented the interim results of the study today and said that according to them there was indeed an increase in antibody levels - "but from the serological study on Sheba employees we see that this is a level that does not protect against Omicron." This was reported this evening (Monday) by Meir Marciano on Channel 13. Experts clash? The convoluted storm surrounding the coronavirus vaccine How can I switch banks with a click for free? • All questions and answers Where are the coronavirus tests performed? What test is done and when? All the information 7 million American children who were vaccinated are not wrong: We got vaccinated and you should get vaccinated too According to Regev Yohai, "The fourth vaccine is probably good for the alpha and delta strains but not for leukomicron. The decision to give a fourth vaccine to vulnerable people was probably right. It gives a little advantage. But not enough advantage to give the vaccine to the entire population." The fourth vaccine study is designed to test the effectiveness of the fourth dose, and is based on serology and immunity of the largest group of subjects in the world, numbering about six thousand people. The study also includes about 270 Sheba healthcare workers, who received a fourth dose of vaccine, some from Pfizer and some from Moderna. The results were compared to those of Sheba workers who did not receive a fourth dose.